Page last updated: 2024-08-24

venlafaxine hydrochloride and Liver Dysfunction

venlafaxine hydrochloride has been researched along with Liver Dysfunction in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alves, G; Falcão, A; Llerena, A; Magalhães, P1
Dorne, JL; Renwick, AG; Slob, W; Walton, K1
Dubarek, W; Kucia, K1

Reviews

2 review(s) available for venlafaxine hydrochloride and Liver Dysfunction

ArticleYear
Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers.
    Drug metabolism and drug interactions, 2014, Volume: 29, Issue:3

    Topics: Age Factors; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Biomarkers; Body Weight; Cyclohexanols; Cytochrome P-450 Enzyme System; Genetic Markers; Humans; Kidney Diseases; Liver Diseases; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Sex Factors; Smoking; Venlafaxine Hydrochloride

2014
[Applications and safety of modern antidepressants in patients with liver diseases].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2007, Volume: 60, Issue:1-2

    Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cyclopropanes; Depressive Disorder; Humans; Liver Diseases; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Piperazines; Risk Factors; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride

2007

Other Studies

1 other study(ies) available for venlafaxine hydrochloride and Liver Dysfunction

ArticleYear
Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2002, Volume: 40, Issue:11

    Topics: Adult; Aged; Aging; Benzhydryl Compounds; Cresols; Cyclohexanols; Cytochrome P-450 CYP2D6; Debrisoquin; Desipramine; Encainide; Ethnicity; Genetic Variation; Humans; Hydroxylation; Infant; Infant, Newborn; Kidney Diseases; Kinetics; Liver Diseases; Metabolic Clearance Rate; Metoprolol; Phenylpropanolamine; Polymorphism, Genetic; Propafenone; Substrate Specificity; Tolterodine Tartrate; Venlafaxine Hydrochloride

2002